From a therapeutic perspective, strategies to reprogram TAMs toward an M1-like state—using checkpoint inhibitors, CSF-1R antagonists, or PI3Kγ inhibitors—aim to restore anti-tumor functions. Here, CSF1R is linked to neoplasm.